Imugene Limited (IUGNF)
IUGNF Stock Price Chart
Explore Imugene Limited interactive price chart. Choose custom timeframes to analyze IUGNF price movements and trends.
IUGNF Company Profile
Discover essential business fundamentals and corporate details for Imugene Limited (IUGNF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Jul 2019
Employees
5.00
Website
https://www.imugene.comCEO
Leslie Chong
Description
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
IUGNF Financial Timeline
Browse a chronological timeline of Imugene Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 26 Feb 2026
Earnings released on 29 Jul 2025
Stock split effective on 2 Jul 2025
Shares were split 1 : 34 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 26 Feb 2025
EPS came in at -$0.00 surpassing the estimated -$0.01 by +34.73%.
Earnings released on 30 Oct 2024
Earnings released on 30 Aug 2024
EPS came in at -$0.01 falling short of the estimated -$0.01 by -11.24%, while revenue for the quarter reached -$1.03M .
Earnings released on 18 Apr 2024
Earnings released on 28 Feb 2024
EPS came in at -$0.01 , while revenue for the quarter reached $2.75M .
Earnings released on 9 Jan 2024
EPS came in at -$0.00 , while revenue for the quarter reached $2.58M .
Earnings released on 30 Jun 2023
EPS came in at -$0.00 , while revenue for the quarter reached $2.31M .
Earnings released on 31 Mar 2023
EPS came in at -$0.00 , while revenue for the quarter reached $2.34M .
Earnings released on 31 Dec 2022
EPS came in at -$0.00 , while revenue for the quarter reached $1.64M .
Earnings released on 30 Sept 2022
EPS came in at -$0.00 , while revenue for the quarter reached $1.56M .
Earnings released on 30 Jun 2022
EPS came in at -$0.00 , while revenue for the quarter reached $2.62M .
Earnings released on 31 Mar 2022
EPS came in at -$0.00 , while revenue for the quarter reached $2.86M .
Earnings released on 30 Dec 2021
EPS came in at -$0.00 , while revenue for the quarter reached $1.94M .
Earnings released on 30 Sept 2021
EPS came in at -$0.00 falling short of the estimated -$0.00 by -35.62%, while revenue for the quarter reached $1.93M .
Earnings released on 30 Jun 2021
EPS came in at -$0.00 , while revenue for the quarter reached $1.18M .
Earnings released on 31 Mar 2021
EPS came in at -$0.00 surpassing the estimated -$0.00 by +13.27%, while revenue for the quarter reached $1.20M .
Earnings released on 30 Dec 2020
EPS came in at -$0.00 , while revenue for the quarter reached $1.57M .
Earnings released on 30 Sept 2020
EPS came in at -$0.00 surpassing the estimated -$0.00 by +52.00%, while revenue for the quarter reached $1.46M .
IUGNF Stock Performance
Access detailed IUGNF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.